Duchembio
Public · 1 known investors
South Korean radiopharmaceutical developer and manufacturer of PET imaging tracers for oncology and neurology, listed on the Korea Exchange.
Also known as DCB · DuChemBio · Duchembio Co., Ltd.
Investors · 1
Company profile
researched Aug 2026Duchembio Co., Ltd. (DuChemBio) is a South Korean radiopharmaceutical company that manufactures and merchandises radiopharmaceuticals and associated medical devices, and also operates as a contract development and manufacturing organization. Established in 2002 and headquartered at 81 Wausan-ro, Mapo-gu, Seoul, the company develops, manufactures and commercializes radiopharmaceutical tracers used in PET/CT and PET/MRI hybrid imaging, with focus areas spanning oncology (including prostate cancer), neurology, Alzheimer's disease and Parkinson's disease.
The company describes itself as operating a fully integrated nuclear diagnostics business model, combining in-house development with manufacturing and distribution. Following a merger with Carecamp Inc. in 2021, it operates 12 radiopharmacy facilities across South Korea. It works with hospitals and research centers in the country and has commercialized both internally developed radiopharmaceutical products and products licensed from international partners. In November 2024 the company filed a securities report with South Korea's Financial Services Commission to begin listing on the Korea Exchange, with the stated aim of growing its radiopharma business.
Business model
Duchembio develops, manufactures and commercializes radiopharmaceutical tracers and related medical devices, and provides contract development and manufacturing services. It also manufactures, supplies and distributes radiopharmaceutical agents licensed from international partners, including for use in clinical and investigator-initiated trials.
Latest developments
Duchembio filed for an IPO in November 2024 and completed a placement of 28,455,220 shares on the Korea Exchange on 20 December 2024 at 8,000 KRW per share, raising approximately 227.6 billion KRW (about $157.6 million).
▸Full profile — market position, technology, go-to-market, geography, history
Market position
Described in partner materials as South Korea's largest radiopharmaceutical company by manufacturing capability and a leader in oncology and neurology PET imaging tracers in that market.
Technology
Radiopharmaceutical tracers for PET/CT and PET/MRI hybrid imaging in oncology and neurology, including manufacture of the zirconium-89 labelled CD8 ImmunoPET agent 89Zr-crefmirlimab berdoxam licensed from ImaginAb.
Go-to-market
Hospitals, research centers and nuclear medicine departments in South Korea, and pharmaceutical sponsors and investigators running clinical and investigator-initiated trials requiring PET imaging agents.
Geography
Headquartered in Seoul (Mapo-gu), South Korea, with 12 radiopharmacy facilities across the country. Its distribution agreement with ImaginAb extends supply capacity to other Asian markets.
History
The company was established in 2002. In 2021 it merged with Carecamp Inc., expanding to 12 radiopharmacy facilities across South Korea. In June 2022 it entered a manufacturing and distribution partnership with US-based ImaginAb. In November 2024 it filed a securities report with South Korea's Financial Services Commission to begin the IPO process on the Korea Exchange, and its shares were placed on 20 December 2024 at 8,000 KRW under ticker 176750.
Compiled by commissioned research from 5 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Timeline · 4
launches, deals, and filingsCompleted an open-subscription IPO on the Korea Exchange under ticker 176750, placing 28,455,220 shares at a final price of 8,000 KRW and raising 227,641.76 million KRW.
$157.6M source ↗
Duchembio Co. Ltd. filed a securities report with South Korea's Financial Services Commission, starting the IPO process to list on the Korea Exchange and grow its radiopharmaceutical business.
ImaginAb and DuChemBio announced an agreement under which DuChemBio manufactures and supplies ImaginAb's investigational CD8 ImmunoPET agent 89Zr-crefmirlimab berdoxam for pharmaceutical-sponsored and investigator-initiated clinical trials in South Korea, with distribution capacity extended to other Asian countries and continuing after regulatory approval.
Following the merger with Carecamp Inc., DuChemBio operates 12 radiopharmacy facilities across South Korea.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
▸Research sources · 5
primary sources listed
- Duchembio files for IPO to grow radiopharma business | BioWorldbioworld.com · web
5 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Duchembio do?
- South Korean radiopharmaceutical developer and manufacturer of PET imaging tracers for oncology and neurology, listed on the Korea Exchange.
- Who are Duchembio's investors?
- Duchembio's investors include Kiwoom Investment.